| Literature DB >> 20186512 |
Veronika Akopian, Peter W Andrews, Stephen Beil, Nissim Benvenisty, Jennifer Brehm, Megan Christie, Angela Ford, Victoria Fox, Paul J Gokhale, Lyn Healy, Frida Holm, Outi Hovatta, Barbara B Knowles, Tenneille E Ludwig, Ronald D G McKay, Takamichi Miyazaki, Norio Nakatsuji, Steve K W Oh, Martin F Pera, Janet Rossant, Glyn N Stacey, Hirofumi Suemori.
Abstract
There are many reports of defined culture systems for the propagation of human embryonic stem cells in the absence of feeder cell support, but no previous study has undertaken a multi-laboratory comparison of these diverse methodologies. In this study, five separate laboratories, each with experience in human embryonic stem cell culture, used a panel of ten embryonic stem cell lines (including WA09 as an index cell line common to all laboratories) to assess eight cell culture methods, with propagation in the presence of Knockout Serum Replacer, FGF-2, and mouse embryonic fibroblast feeder cell layers serving as a positive control. The cultures were assessed for up to ten passages for attachment, death, and differentiated morphology by phase contrast microscopy, for growth by serial cell counts, and for maintenance of stem cell surface marker expression by flow cytometry. Of the eight culture systems, only the control and those based on two commercial media, mTeSR1 and STEMPRO, supported maintenance of most cell lines for ten passages. Cultures grown in the remaining media failed before this point due to lack of attachment, cell death, or overt cell differentiation. Possible explanations for relative success of the commercial formulations in this study, and the lack of success with other formulations from academic groups compared to previously published results, include: the complex combination of growth factors present in the commercial preparations; improved development, manufacture, and quality control in the commercial products; differences in epigenetic adaptation to culture in vitro between different ES cell lines grown in different laboratories.Entities:
Mesh:
Year: 2010 PMID: 20186512 PMCID: PMC2855804 DOI: 10.1007/s11626-010-9297-z
Source DB: PubMed Journal: In Vitro Cell Dev Biol Anim ISSN: 1071-2690 Impact factor: 2.416
Summary of laboratories and cell lines used in the study
| Lab | CODE | Cell lines | |||
|---|---|---|---|---|---|
| Kyoto University | KYOU | WA09 (H9) | KhES-1 | KhES-3 | |
| Karolinska Institute (KI) | KLNI | WA09 (H9) | HS181 | HS420 | |
| WiCell | WCEL | WA09 (H9) | WA13 (H13) | ES03 (HES3) | WA01 (H1) |
| CSCRM, University of Southern California | KUSC | WA09 (H9) | ES03 (HES3) | ES04 (HES4) | |
| UK Stem Cell Bank | UKSCB | WA09 (H9) | HUES9 | NCL5 | Shef2 |
Summary of media and passaging regimes used in this study
| Media no. | Media name | Reference | Passaging enzyme | Matrix | Notes |
|---|---|---|---|---|---|
| 1 | (Li et al. | Dispase | Geltrex or Matrigel | ||
| 2 | (Liu et al. | Dispase | Geltrex or Matrigel | ||
| 3 | (Vallier et al. | Dispase | Gelatin, MEF CM, 10% FBS | Use in 5% CO2 only. Passage when colonies 4–6 times size passaged from MEF-based cultures. Fibronectin can be used as alternative to FBS. | |
| 4 | (Lu et al. | Dispase | Geltrex or Matrigel | ||
| 5 | (Yao et al. | Dispase | Geltrex or Matrigel | ||
| 6 | hESF9 | (Furue et al. | EDTA, 0.2% | Collagen IA (Nitta Gelatina) | Passage day 2 after first passage, thence every 5 d. EDTA/Collagenase can used as alternative passaging reagents. |
| 7 | mTeSR1 | (Ludwig et al. | Dispase | Geltrex or Matrigel | Passage when colonies begin to merge together |
| 8 | STEMPRO | (Wang et al. | Dispase | Geltrex or Matrigel | Harvest cells 1–2 d after colonies touch. Maintain at >200 colonies/60 mm dish |
aNitta Geletin: Type I Collagen (Cellmatrix, Cell Science & Technology Institute, Inc. Japan)
Summary of media formulations used in the study
| Media no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| KO-DMEM | ||||||||
| XVIVO-10 | ✓ | |||||||
| DMEM/F12 | ✓ | ✓ | ✓ | ✓b | ✓ | |||
| IMDM/F12 | ✓ | |||||||
| ESFa | ✓ | |||||||
| N2 | ✓ | ✓ | ||||||
| B27 | ✓ | ✓ | ||||||
| NEAA | 1% | 1% | ✓ | ✓ | 1× | |||
| L-glutamine | 2 mM | 1 mM | 4 mM | 1 mM | 2 mM | 2.94 mM | 542 mg/l | |
| Beta-MercaptoEthanol | 0.1 mM | 0.1 mM | 0.11 mM | 10 µM | 0.098 mM | 0.1 mM | ||
| Insulin | 7 µg/ml | 160 µg/ml | 10 µg/ml | 3.92 µM | ||||
| Transferrin | 15 µg/ml | 88 µg/ml | 5 µg/ml | 0.137 µM | 10 µg/ml | |||
| 2-ethanolamine | 10 µM | |||||||
| Na-selenite | 20 nM | |||||||
| L-ascorbic acid 2-phosphate | 0.1 mg/ml | |||||||
| Monothioglycerol | 450 μM | |||||||
| Cholesterol | ✓ | 1.12 µM | ||||||
| Lipids | ✓ | Oleic acidc | ✓ | Lipoic acid 0.105 mg/l | ||||
| BSA | 5 mg/ml | 0.5 mg/ml | ✓ | 0.195 mM | 2 % | |||
| Pipecolic Acid | 0.984 µM | |||||||
| Activin A | 10 ng/ml | 10 ng/ml | ||||||
| bFGF | 40 ng/ml | 100 ng/ml | 12 ng/ml | 4 ng/ml | 20 ng/ml | 10 ng/ml | 100 ng/ml | 8 ng/ml |
| WNT3A | 100 ng/ml | |||||||
| hFLT3 | 15 ng/ml | |||||||
| HRG1β | 10 ng/ml | |||||||
| LR3-IGF1 | 200 ng/ml | |||||||
| BAFF | 100 ng/ml | |||||||
| TGF-beta | 23.5 pM | |||||||
| GABA | 0.979 mM | |||||||
| LiCl | 0.98 mM | |||||||
| Na Heparin SO4 | ✓ |
aBase medium ESF designed for use with mouse ES cells (Furue et al. 2008)
bModified DMEM/F12 (Ludwig et al. 2006b)
cConjugated with fatty acid free BSA (9.4 µg/ml)
Summary of sources of media components
| Media no. | Media name | Reference | Component | Manufacturer | Catologue no. |
|---|---|---|---|---|---|
| 1 | (Li et al. | XVIVO-10 | Lonza | ||
| NEAA | Invitrogen | 11140-050 | |||
| L-glutamine | Invitrogen | 25030-081 | |||
| Beta-mercaptoethanol | Invitrogen | 21985-023 | |||
| hbFGF | RnD Systems | 3718-FB | |||
| hFLT3 | RnD Systems | 308-FKN/CF | |||
| 2 | (Liu et al. | DMEM/F12 | Invitrogen | 21041-025 | |
| N2 | Invitrogen | 17502-048 | |||
| B27 | Invitrogen | 17504-044 | |||
| L-glutamine | Invitrogen | 25030-081 | |||
| Beta-mercaptoethanol | Invitrogen | 21985-023 | |||
| hbFGF | RnD Systems | 3718-FB | |||
| 3 | (Vallier et al. | IMDM | Invitrogen | 21980-32 | |
| F12 | Invitrogen | 31765-027 | |||
| L-glutamine | Invitrogen | 25030-081 | |||
| Beta-mercaptoethanol | Invitrogen | 21985-023 | |||
| Insulin | Invitrogen | 12585-014 | |||
| Transferrin | Invitrogen | 11105-012 | |||
| Monothioglycerol | Sigma-Aldrich | M6145 | |||
| BSA | Europa bioproducts | EQBAC62 - lot BAC62-624 | |||
| ActivinA | RnD Systems | 338-AC/CF | |||
| hbFGF | RnD Systems | 3718-FB | |||
| 4 | (Lu et al. | DMEM/F12 | Invitrogen | 21041-025 | |
| L-glutamine | Invitrogen | 25030-081 | |||
| Beta-mercaptoethanol | Invitrogen | 21985-023 | |||
| Insulin | Invitrogen | 12585-014 | |||
| Transferrin | Invitrogen | 11105-012 | |||
| Cholesterol | Invitrogen | 12531-018 | |||
| Albumin | Invitrogen | 11021-029 | |||
| hbFGF | RnD Systems | 3718-FB | |||
| WNT3A | RnD Systems | 1324-WN/CF | |||
| BAFF | Invitrogen | PHC1674 | |||
| 5 | (Yao et al. | DMEM/F12 | Invitrogen | 21041-025 | |
| N2 | Invitrogen | 17502-048 | |||
| B27 | Invitrogen | 17504-044 | |||
| NEAA | Invitrogen | 11140-050 | |||
| L-glutamine | Invitrogen | 25030-081 | |||
| Beta-mercaptoethanol | Invitrogen | 21985-023 | |||
| BSA Fraction V | Invitrogen | 15260-037 | |||
| hbFGF | RnD Systems | 3718-FB | |||
| 6 | hESF9 | (Furue et al. | n/a | CSTI | |
| 7 | mTeSR1 | (Ludwig et al. | n/a | Stem Cell Technologies | |
| 8 | STEMPRO | (Wang et al. | n/a | Invitrogen |
Addresses of suppliers:
Invitrogen Corporation, 5791 Van Allen Way, Carlsbad, CA 92008, USA.
RnD Systems Inc., 614 McKinley Place N.E., Minneapolis, MN 55413, USA.
Stem Cell Technologies 570 West Seventh Avenue, Suite 400, Vancouver, BC, Canada V5Z 1B3
CSTI: Cell Science & Technology Institute, Inc 982-0262 1-chome, Aoba-ku, Sendai, Miyagi, Japan.
Figure 1.(A) Summary test results. (B) Results of the retest of the media by UKSCB. For most tests new growth factors were obtained however for testing of medium no. 3 three different batches of Activin A were used. ISCI-GF: Original growth factor batch used in the ISCI study. UKSCB-GF: New Growth factor obtained for the retest. LV-GF: Activin A obtained from the originating laboratory.
Figure 2.Representative photomicrographs and cell counts. (A) Photomicrographs of KhES-1 and H9 (WA09) respectively grow to ten passages in mTeSR1 and STEMPRO, respectively. (B) Representative cell counts from each passage for the cell lines WA09 (H9), KhES-1, and KhES-3.
Figure 3.Representative flow cytometry data. Representative flow cytometry data expressed as percentage of cells called positive for three cell lines H9, KhES-1, and KhES-3 at passage 0 in Knockout Serum Replacer, FGF-2, and mouse embryonic fibroblast feeder cells and at passage 5 and 10 for cells grown in mTeSR1 and STEMPRO.